Adage Capital Partners Gp, L.L.C. Crinetics Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.6 Billion
- Q3 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 40,000 shares of CRNX stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,000
Previous 201,048
80.1%
Holding current value
$1.61 Million
Previous $9 Million
77.31%
% of portfolio
0.0%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding CRNX
# of Institutions
242Shares Held
80.1MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$253 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$251 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$237 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$199 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$180 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.17B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...